Science

Dec 29, 2024, 10:10

Neoadjuvant atezolizumab plus chemotherapy for resectable NSCLC

Journal for ImmunoTherapy of Cancer posted on X about recent paper by Brian S. Henick et al., titled “Neoadjuvant atezolizumab + chemotherapy for resectable NSCLC: 3-year clinical update of phase II clinical trial results and translational findings“.

Authors: Brian S. Henick, Peter D. Koch, Justin F. Gainor, Mark M. Awad, Codruta Chiuzan, Stephanie Izard, Yohanna Georgis, Samyukta Mallick, Robert F. Garofano, Cheryl V. Wong, Anjali Saqi, Jessica Grindheim, Katja Schulze, Joshua R. Sonett, Naiyer A. Rizvi, Benjamin Izar, Alison M. Taylor, Catherine A. Shu

“New JITC article: Neoadjuvant atezolizumab + chemotherapy for resectable NSCLC: 3-year clinical update of phase II clinical trial results and translational findings.”

Alison M. Taylor Anjali Saqi Benjamin Izar Brian S Henick cancer Catherine A. Shu Cheryl V. Wong Codruta Chiuzan Jessica Grindheim Joshua R. Sonett Journal for ImmunoTherapy of Cancer Justin F. Gainor Katja Schulze Mark M. Awad Naiyer A. Rizvi NSCLC OncoDaily Oncology Peter D. Koch Robert F. Garofano Samyukta Mallick Stephanie Izard Yohanna Georgis

Aladina Foundation was Honored with the Yvonne Humanitarian Award by OncoDaily

Rod Stewart and Prostate Cancer: How He Went Against, How He Survived, and More

Kimryn Rathmell: The year in cancer - 24 advances in 2024

Celebrating the Holiday Magic with Medical Community

Melanie Griffith and Skin Cancer: How She Went Against, How She Survived, and More

Special Coverage